{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:47:47Z","timestamp":1778032067671,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the relationship between symptom and functional improvement and remission in children and adolescents with attention-deficit\/hyperactivity disorder (ADHD) enrolled in an 11-week open-label dose-optimization phase of an methylphenidate extended release (MPH-MLR) pivotal study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Assessments included the Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) and ADHD Rating Scale, Fourth Edition (ADHD-RS-IV). Definitions included the following: symptom improvement (\u226530% decrease in ADHD-RS-IV total score); symptom remission (ADHD-RS-IV total score \u226418); functional improvement (decrease in WFIRS-P total score \u22650.25 [minimally important difference]); and functional remission (WFIRS-P total score \u22640.65).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Two hundred children completed the open-label phase. At initial assessment, functional impairment was evident across all WFIRS-P domains and similar between children and adolescents. Those who were treatment naive had more functional impairment (WFIRS-P total: 0.82 vs. 0.70,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.02). Significant improvements in all WFIRS-P domains were noted at open-label end (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with the largest improvement in Learning. At open-label end, 94% of children and adolescents demonstrated symptom improvement, of which 57% also showed functional improvement, and 75% of children and adolescents showed symptom remission, of which 81% also showed functional remission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Children and adolescents treated with MPH-MLR showed moderate-to-large improvement in functioning during 3 months of treatment, both overall and in specific domains. However, a significant number of those who would be considered symptomatic responders failed to show improvement in functioning or continue to have significant functional impairment. Treatment with MPH-MLR showed that both symptomatic and functional remission are achievable goals. Identification of children and adolescents who have been successfully treated for their symptoms, but continue to suffer functional impairment, will allow us to offer additional targeted treatment interventions over and above medication to address residual difficulties.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2017.0166","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T12:55:01Z","timestamp":1532350501000},"page":"521-529","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":27,"title":["Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial"],"prefix":"10.1177","volume":"28","author":[{"given":"Margaret","family":"Weiss","sequence":"first","affiliation":[{"name":"Child Study Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Childress","sequence":"additional","affiliation":[{"name":"Center for Psychiatry and Behavioral Medicine, Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Mattingly","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University School of Medicine"},{"name":"Midwest Research Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Earl","family":"Nordbrock","sequence":"additional","affiliation":[{"name":"Rhodes Pharmaceuticals L.P."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Kupper","sequence":"additional","affiliation":[{"name":"Rhodes Pharmaceuticals L.P."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akwete L.","family":"Adjei","sequence":"additional","affiliation":[{"name":"Rhodes Pharmaceuticals L.P."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,10,9]]},"reference":[{"key":"e_1_3_4_2_1","volume-title":"Coventry (Rhode Island)","author":"Aptensio XR\u00ae capsules [package insert].","unstructured":"Aptensio XR\u00ae capsules [package insert].. Coventry (Rhode Island), Rhodes Pharmaceuticals L.P. Revised May 2015."},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2013.0135"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/1073191102009001003"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0193-z"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0095-5"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-009-0056-1"},{"key":"e_1_3_4_9_1","unstructured":"Canadian ADHD Resource Alliance: CADDRA ADHD Assessment Toolkit (CATT) Forms.. 2011. Available at: www.caddra.ca\/cms4\/pdfs\/caddraGuidelines2011_Toolkit.pdf Accessed October27 2014."},{"key":"e_1_3_4_10_1","unstructured":"Canadian ADHD Resource Alliance: Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P).. 2000. Available at: www.caddra.ca\/cms4\/pdfs\/caddraGuidelines2011WFIRS_P.pdf Accessed June22 2016."},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.11.012"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054717723984"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054716661234"},{"key":"e_1_3_4_14_1","volume-title":"ADHD Rating Scale\u2013IV: Checklist Norms, and Clinical Interpretation","author":"DuPaul GJ","year":"1998","unstructured":"DuPaul GJ, , Power TJ, , Anastopoulos AD, , Reid R: ADHD Rating Scale\u2013IV: Checklist Norms, and Clinical Interpretation. New York, Guilford Press, 1998."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpepsy\/jsp004"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.11r01336"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-015-0379-1"},{"key":"e_1_3_4_18_1","volume-title":"ECDEU Assessment Manual for Psychopharmacology\u2014Revised (DHEW Publ No. ADM 76-338)","author":"Guy W","year":"1976","unstructured":"Guy W: ECDEU Assessment Manual for Psychopharmacology\u2014Revised (DHEW Publ No. ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Services, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054717738084"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852916000353"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.59.1.12"},{"key":"e_1_3_4_22_1","volume-title":"Clinical response and symptomatic remission with Aptensio XR\u00ae (methylphenidate extended-release capsules) in children and adolescents with ADHD","author":"Mattingly G","year":"2017","unstructured":"Mattingly G, , Childress A, , Nordbrock E, , Adjei A, , Kupper RJ, , Weiss M: Clinical response and symptomatic remission with Aptensio XR\u00ae (methylphenidate extended-release capsules) in children and adolescents with ADHD. American Professional Society ADHD and Related Disorders (APSARD) Annual Meeting, Washington, DC, 2017."},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e31819c23d0"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-015-0718-0"},{"key":"e_1_3_4_25_1","first-page":"111","article-title":"Reliablity and validity of Weiss Functional Impairment Rating Scale (WFIRS)-Thai version in children and adolescents with attention deficit hyperactivity disorder","volume":"60","author":"Punyapas S","year":"2015","unstructured":"Punyapas S, , Pornnoppadol C, , Boon-yasidhi V, , Likhitkiatikhachorn P: Reliablity and validity of Weiss Functional Impairment Rating Scale (WFIRS)-Thai version in children and adolescents with attention deficit hyperactivity disorder. J Psychiatric Assoc Thai, 60:111\u2013126, 2015.","journal-title":"J Psychiatric Assoc Thai"},{"key":"e_1_3_4_26_1","first-page":"767","article-title":"Reliability and validity of the Chinese version of Weiss Functional Impairment Scale\u2013Parent Form for school age children","volume":"25","author":"Qian Y","year":"2011","unstructured":"Qian Y, , Du Q, , Qu S, , Wang Y: Reliability and validity of the Chinese version of Weiss Functional Impairment Scale\u2013Parent Form for school age children. Chin Ment Health J, 25:767\u2013771, 2011.","journal-title":"Chin Ment Health J"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0601"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.11.006"},{"key":"e_1_3_4_29_1","first-page":"953","article-title":"Does guanfacine extended release impact functional impairment in children with attention-deficit\/hyperactivity disorder?","volume":"29","author":"Stein MA","year":"2015","unstructured":"Stein MA, , Sikirica V, , Weiss MD, , Robertson B, , Lyne A, , Newcorn JH: Does guanfacine extended release impact functional impairment in children with attention-deficit\/hyperactivity disorder?. Results from a randomized controlled trial. CNS Drugs, 29:953\u2013962, 2015.","journal-title":"Results from a randomized controlled trial. CNS Drugs"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0018"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200102000-00011"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12402-014-0158-6"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1514-8"},{"key":"e_1_3_4_34_1","volume-title":"Reliability and validity of the Weiss Functional Impairment Rating Scale","author":"Weiss MD","year":"2007","unstructured":"Weiss MD, , Brooks BL, , Iverson GL, , Lee B, , Dickson R, , Gibbins C, , Wasdell M: Reliability and validity of the Weiss Functional Impairment Rating Scale. American Academy of Child and Adolescent Psychiatry 64th Annual Meeting, Washington, DC, 2007."},{"key":"e_1_3_4_35_1","volume-title":"Weiss Functional Impairment Rating Scale\u2013Parent Report (WFIRS-P): A new measure of impairment associated with ADHD","author":"Weiss MD","year":"2005","unstructured":"Weiss MD, , Wasdell MB, , Bomben MM, , Caney SV: Weiss Functional Impairment Rating Scale\u2013Parent Report (WFIRS-P): A new measure of impairment associated with ADHD. 158th Annual Meeting of the American Psychiatric Association, Atlanta, GA, 2005."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2014.0100"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0241-3"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2015.08.016"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2017.0166","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2017.0166","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2017.0166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:55:11Z","timestamp":1777388111000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2017.0166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1089\/cap.2017.0166"],"URL":"https:\/\/doi.org\/10.1089\/cap.2017.0166","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}